These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

385 related items for PubMed ID: 29417313

  • 21. Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.
    Rees VE, Yadav R, Rogers KE, Bulitta JB, Wirth V, Oliver A, Boyce JD, Peleg AY, Nation RL, Landersdorfer CB.
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30104278
    [Abstract] [Full Text] [Related]

  • 22. Bacterial biofilm in chronic airway infection.
    Ohgaki N.
    Kansenshogaku Zasshi; 1994 Jan; 68(1):138-51. PubMed ID: 8138670
    [Abstract] [Full Text] [Related]

  • 23. Fabrication of inhaled hybrid silver/ciprofloxacin nanoparticles with synergetic effect against Pseudomonas aeruginosa.
    Al-Obaidi H, Kalgudi R, Zariwala MG.
    Eur J Pharm Biopharm; 2018 Jul; 128():27-35. PubMed ID: 29654885
    [Abstract] [Full Text] [Related]

  • 24. Inhaled or nebulised ciprofloxacin for the maintenance treatment of bronchiectasis.
    Cartlidge MK, Hill AT.
    Expert Opin Investig Drugs; 2017 Sep; 26(9):1091-1097. PubMed ID: 28778139
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Reinforcement of the bactericidal effect of ciprofloxacin on Pseudomonas aeruginosa biofilm by hyperbaric oxygen treatment.
    Kolpen M, Mousavi N, Sams T, Bjarnsholt T, Ciofu O, Moser C, Kühl M, Høiby N, Jensen PØ.
    Int J Antimicrob Agents; 2016 Feb; 47(2):163-7. PubMed ID: 26774522
    [Abstract] [Full Text] [Related]

  • 28. Efficacy of a ciprofloxacin/amikacin combination against planktonic and biofilm cultures of susceptible and low-level resistant Pseudomonas aeruginosa.
    Soares A, Alexandre K, Lamoureux F, Lemée L, Caron F, Pestel-Caron M, Etienne M.
    J Antimicrob Chemother; 2019 Nov 01; 74(11):3252-3259. PubMed ID: 31424553
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.
    Serisier DJ.
    Drugs Today (Barc); 2012 May 01; 48(5):339-51. PubMed ID: 22645722
    [Abstract] [Full Text] [Related]

  • 32. Inhaled antibiotics: A promising drug delivery strategies for efficient treatment of lower respiratory tract infections (LRTIs) associated with antibiotic resistant biofilm-dwelling and intracellular bacterial pathogens.
    Islam N, Reid D.
    Respir Med; 2024 Jun 01; 227():107661. PubMed ID: 38729529
    [Abstract] [Full Text] [Related]

  • 33. Phenotypic shift in Pseudomonas aeruginosa populations from cystic fibrosis lungs after 2-week antipseudomonal treatment.
    Fernández-Barat L, Ciofu O, Kragh KN, Pressler T, Johansen U, Motos A, Torres A, Hoiby N.
    J Cyst Fibros; 2017 Mar 01; 16(2):222-229. PubMed ID: 27651273
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
    Meers P, Neville M, Malinin V, Scotto AW, Sardaryan G, Kurumunda R, Mackinson C, James G, Fisher S, Perkins WR.
    J Antimicrob Chemother; 2008 Apr 01; 61(4):859-68. PubMed ID: 18305202
    [Abstract] [Full Text] [Related]

  • 37. Co-spray-dried mannitol-ciprofloxacin dry powder inhaler formulation for cystic fibrosis and chronic obstructive pulmonary disease.
    Adi H, Young PM, Chan HK, Agus H, Traini D.
    Eur J Pharm Sci; 2010 Jun 14; 40(3):239-47. PubMed ID: 20371286
    [Abstract] [Full Text] [Related]

  • 38. Novel Inhaled Combination Powder Containing Amorphous Colistin and Crystalline Rifapentine with Enhanced Antimicrobial Activities against Planktonic Cells and Biofilm of Pseudomonas aeruginosa for Respiratory Infections.
    Zhou QT, Sun SP, Chan JG, Wang P, Barraud N, Rice SA, Wang J, Li J, Chan HK.
    Mol Pharm; 2015 Aug 03; 12(8):2594-603. PubMed ID: 25423590
    [Abstract] [Full Text] [Related]

  • 39. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
    Price KE, Orazi G, Ruoff KL, Hebert WP, O'Toole GA, Mastoridis P.
    PLoS One; 2015 Aug 03; 10(10):e0141192. PubMed ID: 26506004
    [Abstract] [Full Text] [Related]

  • 40. Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides.
    Dosler S, Karaaslan E.
    Peptides; 2014 Dec 03; 62():32-7. PubMed ID: 25285879
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.